Worth Venture Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Worth Venture Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-51,200	Closed	-$99K	–	119
2019 Q2	$99K	Sell	51,200 -16,300	-24%	-$209K	0.05%	75
2019 Q1	$43K	Sell	67,500 -33,600	-33%	-$429K	0.02%	86
2018 Q4	$2K	Buy	101,100 +41,100	+69%	+$664K	﹤0.01%	91
2018 Q3	$207K	Sell	60,000 -29,000	-33%	-$606K	0.16%	71
2018 Q2	$183K	Sell	89,000 -20,000	-18%	-$406K	0.15%	68
2018 Q1	$579K	Buy	109,000 +63,700	+141%	+$1.24M	0.5%	43
2017 Q4	$105K	Buy	+45,300	New	+$699K	0.12%	83

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Worth Venture Partners's ITCI Position: Q2 2024 in Review

Worth Venture Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 3,300 shares — an estimated $228K sold.

Worth Venture Partners first reported a position in ITCI in Q1 2024 and held it in 1 quarter. The position peaked at $228K in Q1 2024. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

Worth Venture Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
Worth Venture Partners sold 3,300 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $228K.
Worth Venture Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 1 quarter.
Worth Venture Partners's Intra-Cellular Therapies Inc. position peaked at $228K in Q1 2024.
376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Worth Venture Partners's 13F filing for Q2 2024, filed 14 Aug 2024.